ConductScience.org, home

Paper40445239

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.

Bopp AR and 10 others. Cancer Immunol Immunother, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Papers, record 40445239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40445239

Download JSON
Cell line
CAL-27113 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-03-31
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bopp ARAnna R
2Lamenza FFFelipe F
3Upadhaya PPuja
4Ryan NMNathan M
5Kazmierowicz NNatalie
6Jordanides PPPete P
7Siddiqui AArham
8Pracha SHSherefuddin H
9Roth PPeyton
10Iwenofu OHO Hans
11Oghumu SSteve

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PyrimidinesMajor topic
Agammaglobulinaemia Tyrosine KinaseMajor topic
PyrazolesMajor topic
Squamous Cell Carcinoma of Head and NeckMajor topic
Head and Neck NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
T-LymphocytesMajor topic
Carcinoma, Squamous CellMajor topic
Piperidines
Animals
Adenine
Mice
Humans
Tumor Microenvironment
Cell Line, Tumor
Xenograft Model Antitumor Assays
Lymphocytes, Tumor-Infiltrating
Tyrosine Kinase Inhibitors

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
DP1 DA054344NIDA NIH HHSUnited StatesDP1DA054344PubMed and NIHNIH RePORTER
R01 DE033906NIDCR NIH HHSUnited StatesR01DE033906PubMedNIH RePORTER
RSG-19079-01-TBGAmerican Cancer SocietyPubMedPubMed
DP1DA054344NIH HHSUnited StatesDP1DA054344PubMed and NIHNIH RePORTER

Download CSV of grants

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129709262New Therapies in Head and Neck Cancer.Trends Cancer2018https://conductscience.org/library/papers/29709262PubMed
233243986Head and neck squamous cell carcinoma.Nat Rev Dis Primers2020https://conductscience.org/library/papers/33243986PubMed
331307547The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).J Immunother Cancer2019https://conductscience.org/library/papers/31307547PubMed
429355614Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.Semin Cancer Biol2018https://conductscience.org/library/papers/29355614PubMed
533477635Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma.Cancers (Basel)2021https://conductscience.org/library/papers/33477635PubMed
634307353Bruton's Tyrosine Kinase and Its Isoforms in Cancer.Front Cell Dev Biol2021https://conductscience.org/library/papers/34307353PubMed
731764119Bruton Tyrosine Kinase Inhibitors: Present and Future.Cancer J2019https://conductscience.org/library/papers/31764119PubMed
833122850Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.Leukemia2021https://conductscience.org/library/papers/33122850PubMed
935456016Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.Cells2022https://conductscience.org/library/papers/35456016PubMed
1029455639Role of Bruton's tyrosine kinase in B cells and malignancies.Mol Cancer2018https://conductscience.org/library/papers/29455639PubMed
1124658273Targeting Bruton's tyrosine kinase in B cell malignancies.Nat Rev Cancer2014https://conductscience.org/library/papers/24658273PubMed
1226383180Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.Cancer Biol Ther2015https://conductscience.org/library/papers/26383180PubMed
1326036311Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Oncotarget2015https://conductscience.org/library/papers/26036311PubMed
1436593070Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.J Immunother Cancer2023https://conductscience.org/library/papers/36593070PubMed
1532025027Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.Br J Cancer2020https://conductscience.org/library/papers/32025027PubMed
1623913792A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.Genes Chromosomes Cancer2013https://conductscience.org/library/papers/23913792PubMed
1731238520Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer.Cancers (Basel)2019https://conductscience.org/library/papers/31238520PubMed
1834164404p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors.Front Cell Dev Biol2021https://conductscience.org/library/papers/34164404PubMed
1930733667Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.Front Mol Neurosci2019https://conductscience.org/library/papers/30733667PubMed
2031200752p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.J Exp Clin Cancer Res2019https://conductscience.org/library/papers/31200752PubMed

See all 52 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42612021Myeloid-derived MIF is a central regulator of MDSC-driven T-cell dysfunction in head and neck squamous cell carcinoma.Oncoimmunology2026https://conductscience.org/library/papers/42612021PubMed
41818928Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.Oral Oncol2026https://conductscience.org/library/papers/41818928PubMed
41598706Diagnostic, Prognostic, and Predictive Molecular Biomarkers in Head and Neck Squamous Cell Carcinoma: A Comprehensive Review.J Clin Med2026https://conductscience.org/library/papers/41598706PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40445239

GET https://conductscience.org/api/papers/v1/40445239/references?page=2